Zoetis Inc. (zts)
ZTS — Company Overview
Investors tracking ZTS follow a Drug Manufacturers - Specialty & Generic name listed on NYQ within Healthcare.
| Ticker | ZTS |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Exchange | NYQ |
| Market cap | $29.59B |
| Last price | $71.61 |
| Size category | Large Cap |
ZTS — Business Description
The business profile of Zoetis Inc. (ZTS) reflects its role in Drug Manufacturers - Specialty & Generic. Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products,…
Official website: https://www.zoetis.com.
ZTS — Investment Thesis
Zoetis Inc. (ZTS) attracts investors weighing Drug Manufacturers - Specialty & Generic fundamentals against current market pricing.
- Revenue is contracting at roughly -0.2% year-over-year (public data).
- Trailing P/E near 11.90× suggests a value-oriented earnings multiple.
- Dividend yield near 2.9% adds an income component to total return.
- Equity market capitalization is approximately $29.59B.
See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.
ZTS — Financial Health
ZTS financial profile reflects operating efficiency and capital structure using available market fundamentals.
Profit margin of 27.7% indicates solid bottom-line conversion. Positive free cash flow of $2.02B supports balance-sheet flexibility. Debt-to-equity of 294.00 warrants monitoring in a higher-rate environment.
| Trailing P/E | 11.90× |
| Forward P/E | 10.96× |
| Price / Sales | 3.11× |
| Price / Book | 9.14× |
| Gross margin | 71.7% |
| Operating margin | 40.7% |
| Profit margin | 27.7% |
| Return on equity | 64.9% |
| Debt / Equity | 294.00 |
| Free cash flow | $2.02B |
ZTS — Growth Outlook
Growth outlook for Zoetis Inc. (ZTS) depends on demand trends in Drug Manufacturers - Specialty & Generic and the company's ability to convert revenue into sustainable earnings.
- Revenue decline of -0.2% highlights near-term demand headwinds.
- Earnings growth of 1.2% year-over-year supports improving profitability.
- Price is 51.9% below the 52-week high.
- Shares trade 1.9% above the 52-week low — limited rebound so far.
ZTS — Competitive Position
Zoetis Inc. (ZTS) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.
- Competes within Healthcare, specifically in Drug Manufacturers - Specialty & Generic.
- Market capitalization of $29.59B places ZTS among large-cap peers.
- Gross margin near 71.7% may reflect pricing power or favorable mix.
ZTS — Strengths
Strengths for Zoetis Inc. (ZTS) inferred from public financial metrics:
- Earnings growth of 1.2% year-over-year.
- Return on equity near 64.9% — efficient use of shareholder capital.
- Gross margin of 71.7% supports competitive unit economics.
- Positive free cash flow ($2.02B).
- Dividend yield of 2.9% for income-oriented holders.
- Large Cap scale ($29.59B) may provide distribution and funding advantages.
ZTS — Weaknesses
Weaknesses and pressure points for Zoetis Inc. (ZTS) based on available data:
- Revenue contraction of -0.2% year-over-year.
- Elevated debt-to-equity (294.00).
- Price 52% below the 52-week high — sustained negative sentiment.
ZTS — Opportunities
- Trading 1.9% above the 52-week low — potential recovery if fundamentals stabilize.
- Dividend yield of 2.9% appeals to total-return investors.
- Positive free cash flow enables reinvestment, debt reduction, or shareholder returns.
ZTS — Risks
- Leverage (debt/equity 294.00) raises sensitivity to credit conditions.
- Negative revenue growth may signal share loss or cyclical pressure.
ZTS — Summary
Zoetis Inc. (ZTS) is a large-cap Healthcare company focused on Drug Manufacturers - Specialty & Generic, listed on NYQ. Last price $71.61 with market cap $29.59B. Trailing P/E 11.90×. Revenue declined -0.2% year-over-year per public data. Notable strengths include earnings growth of 1.2% year-over-year. Key watch items include revenue contraction of -0.2% year-over-year. Review free estimates and earnings pages for ZTS; upgrade for institutional ownership and live headlines.
Start Free — open ZTS in Vest Terminal
Access live data, filings, ownership, and analysis for Zoetis Inc..
Zoetis Inc. FAQ
What does Zoetis Inc. (ZTS) do?
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationall…
What is ZTS's P/E ratio?
Zoetis Inc. has a trailing P/E of 11.90× based on publicly available market data.
Does ZTS pay a dividend?
Indicated dividend yield: 2.9%. Confirm ex-dates and payout history in Vest Terminal.
What sector is ZTS in?
Zoetis Inc. is classified in Healthcare (Drug Manufacturers - Specialty & Generic) on NYQ.
What is ZTS's market capitalization?
Approximate market cap: $29.59B.
What are the main risks for ZTS?
Key risks include negative revenue growth, among factors on this page.
What are the strengths of ZTS?
Potential positives include earnings growth of 1.2% year-over-year, return on equity near 64.9% — efficient use of shareholder capital.
Where can I get analyst estimates for ZTS?
Public analyst price targets and consensus for Zoetis Inc. are on the free /stocks/zts/estimates page. Deeper estimate history and models are available in Vest Terminal.